Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12477)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 15, 2019 (publication date) through Apr 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132 [PMID: 30788048 DOI: 10.4239/wjd.v10.i2.114] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm |
| Number | Citing Articles |
| 1 |
Haofei Hu, Yong Han, Changchun Cao, Yongcheng He. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. Journal of Translational Medicine 2022; 20(1) doi: 10.1186/s12967-022-03611-4
|
| 2 |
Emmanouil Koullias, Maria Papavdi, Stavros Athanasopoulos, Asimina Mitrakou, Melanie Deutsch, Pavlos Zoumpoulis, Emmanuel Manesis, Anastasia Thanopoulou, John Koskinas. Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus. Cureus 2024; doi: 10.7759/cureus.53813
|
| 3 |
Mengyuan Li, Lin Yao, Haipeng Huang, Guan Wang, Bin Yu, Haizhu Zheng, Hongfeng Wang. Acupuncture for type 2 diabetes mellitus with nonalcoholic fatty liver disease. Medicine 2021; 100(21): e26043 doi: 10.1097/MD.0000000000026043
|
| 4 |
Amélio F. Godoy-Matos, Cynthia Melissa Valério, Wellington S. Silva Júnior, João Marcello de Araujo-Neto, Marcello Casaccia Bertoluci. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes. Diabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01259-2
|
| 5 |
Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo. Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes. Advances in Therapy 2022; 39(11): 4837 doi: 10.1007/s12325-022-02310-2
|
| 6 |
Georgios S. Papaetis, Michalis K. Picolos, Anastasia Sacharidou. Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?. Archives of Medical Science – Atherosclerotic Diseases 2025; 10(1): 1 doi: 10.5114/amsad/202298
|
| 7 |
Rodrigo Oliveira Moreira, Cynthia Melissa Valerio, Cristiane Alves Villela-Nogueira, Cintia Cercato, Fernando Gerchman, Ana Maria Pita Lottenberg, Amélio Fernando Godoy-Matos, Ricardo de Andrade Oliveira, Carlos Eduardo Brandão Mello, Mário Reis Álvares-da-Silva, Nathalie Carvalho Leite, Helma Pinchemel Cotrim, Edison Roberto Parisi, Giovanni Faria Silva, Paulo Augusto Carvalho Miranda, Bruno Halpern, Claudia Pinto Oliveira. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso). Archives of Endocrinology and Metabolism 2023; 67(6) doi: 10.20945/2359-4292-2023-0123
|
| 8 |
Ke He, Jingxin Li, Wang Xi, Jun Ge, Jingna Sun, Zeng Jing. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2022; 185: 109791 doi: 10.1016/j.diabres.2022.109791
|
| 9 |
Jing Wang, Shuoqiang Bao, Qi An, Caihong Li, Juan Feng. Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1544012
|
| 10 |
Albert Macaire C. Ong Lopez, Janine Audrei T. Pajimna. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-52603-5
|
| 11 |
Jayanta Paul. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egyptian Liver Journal 2020; 10(1) doi: 10.1186/s43066-020-00043-x
|
| 12 |
Mona Ahmed Amin, Noha Adly Sadik, Hala Ahmed Saad, Mohammed Fawzy, Hend Abdallah Elsheimy. The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease. Internal and Emergency Medicine 2025; doi: 10.1007/s11739-025-03902-w
|
| 13 |
Mario Simental-Mendía, Adriana Sánchez-García, Mariana Rodríguez-Ramírez, Luis E. Simental-Mendía. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research 2021; 163: 105319 doi: 10.1016/j.phrs.2020.105319
|
| 14 |
Stewart G. Albert, Emily M. Wood. Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021; 15(5): 102232 doi: 10.1016/j.dsx.2021.102232
|
| 15 |
Kabeer Ali, Saeed R Mohammed, Rishi Deonarine, Surujpal Teelucksingh. Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers. Cureus 2021; doi: 10.7759/cureus.17573
|
| 16 |
Stephen A. Harrison, Federico Perez Manghi, William B. Smith, Diana Alpenidze, Diego Aizenberg, Naomi Klarenbeek, Chi-Yi Chen, Eli Zuckerman, Eric Ravussin, Phunchai Charatcharoenwitthaya, Pin-Nan Cheng, Helena Katchman, Samuel Klein, Ziv Ben-Ari, Anisha E. Mendonza, Yiming Zhang, Miljen Martic, Shenglin Ma, Sheena Kao, Sandra Tanner, Alok Pachori, Michael K. Badman, YanLing He, Chinweike Ukomadu, Eric Sicard. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nature Medicine 2022; 28(7): 1432 doi: 10.1038/s41591-022-01861-9
|
| 17 |
Rajesh Jain, Natrajan Bhavatharini, Thangavel Saravanan, Veeraswamy Seshiah, Nishchal Jain. Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes. Cureus 2022; doi: 10.7759/cureus.32573
|
| 18 |
Paula Luque-Linero, Luis Castilla-Guerra. Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting. European Cardiology Review 2024; 19 doi: 10.15420/ecr.2023.19
|
| 19 |
K M Prasanna Kumar, A G Unnikrishnan, Pankaj Jariwala, Ashwani Mehta, Richa Chaturvedi, Sagar Panchal, Preet Lakhani, Rachana Acharya, Jitendra Dixit. SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective. Indian Journal of Endocrinology and Metabolism 2024; 28(1): 11 doi: 10.4103/ijem.ijem_377_23
|
| 20 |
Amy W Rachfal, Struan FA Grant, Stanley S Schwartz. The Diabetes Syndrome – A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms. International Journal of General Medicine 2021; : 923 doi: 10.2147/IJGM.S305156
|
| 21 |
Yehuda Handelsman. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Advances in Therapy 2019; 36(10): 2567 doi: 10.1007/s12325-019-01054-w
|
| 22 |
Guan Wang, Mengyuan Li, Shuo Yu, Mengqi Guan, Shiqi Ma, Zhen Zhong, Yihui Guo, Xiangyang Leng, Haipeng Huang. Tandem mass tag-based proteomics analysis of type 2 diabetes mellitus with non-alcoholic fatty liver disease in mice treated with acupuncture. Bioscience Reports 2022; 42(1) doi: 10.1042/BSR20212248
|
| 23 |
Angel N Borisov, Alexander Kutz, Emanuel R Christ, Markus H Heim, Fahim Ebrahimi. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. The Journal of Clinical Endocrinology & Metabolism 2023; 108(11): 2940 doi: 10.1210/clinem/dgad249
|
| 24 |
Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin. Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder. Current Drug Therapy 2024; 19(1): 20 doi: 10.2174/1574885518666230417111247
|
| 25 |
Amélio F. Godoy-Matos, Wellington S. Silva Júnior, Cynthia M. Valerio. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome 2020; 12(1) doi: 10.1186/s13098-020-00570-y
|
| 26 |
Xiaojing Huang, Huiling Chen, Song Wen, Meiyuan Dong, Ligang Zhou, Xinlu Yuan. Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs. Diabetes, Metabolic Syndrome and Obesity 2023; : 1809 doi: 10.2147/DMSO.S411400
|
| 27 |
Stephan C. Bischoff, Johann Ockenga, Ahad Eshraghian, Rocco Barazzoni, Luca Busetto, Marjo Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Haluk Tarik Kani, Wafaa Khannoussi, Laurence Lacaze, Miguel Léon-Sanz, Juan M. Mendive, Michael W. Müller, Frank Tacke, Anders Thorell, Darija Vranesic Bender, Arved Weimann, Cristina Cuerda. Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline. Clinical Nutrition 2023; 42(6): 987 doi: 10.1016/j.clnu.2023.03.021
|
| 28 |
Abdulrahman Ismaiel, Dan L. Dumitrascu. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. American Journal of Therapeutics 2023; 30(3): e242 doi: 10.1097/MJT.0000000000001174
|
| 29 |
Ryo Bamba, Takuro Okamura, Yoshitaka Hashimoto, Saori Majima, Takafumi Senmaru, Emi Ushigome, Naoko Nakanishi, Mai Asano, Masahiro Yamazaki, Hiroshi Takakuwa, Masahide Hamaguchi, Michiaki Fukui. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice. Journal of Cachexia, Sarcopenia and Muscle 2022; 13(1): 574 doi: 10.1002/jcsm.12814
|
| 30 |
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, Marjo Campmans‐Kuijpers, Vincenzo Cardinale, Irit Chermesh, Ahad Eshraghian, Haluk Tarik Kani, Wafaa Khannoussi, Laurence Lacaze, Miguel Léon‐Sanz, Juan M. Mendive, Michael W. Müller, Johann Ockenga, Frank Tacke, Anders Thorell, Darija Vranesic Bender, Arved Weimann, Cristina Cuerda. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterology Journal 2022; 10(7): 663 doi: 10.1002/ueg2.12280
|
| 31 |
Shih-Chieh Shao, Liang-Tseng Kuo, Rong-Nan Chien, Ming-Jui Hung, Edward Chia-Cheng Lai. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Research & Care 2020; 8(2): e001956 doi: 10.1136/bmjdrc-2020-001956
|
| 32 |
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof J. Filipiak, Aleksandra Gąsecka. The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?. Journal of Cardiovascular Development and Disease 2023; 10(11): 465 doi: 10.3390/jcdd10110465
|
| 33 |
Philipp Kasper, Anna Martin, Sonja Lang, Fabian Kütting, Tobias Goeser, Münevver Demir, Hans-Michael Steffen. NAFLD and cardiovascular diseases: a clinical review. Clinical Research in Cardiology 2021; 110(7): 921 doi: 10.1007/s00392-020-01709-7
|
| 34 |
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 2021; 27(2): 221 doi: 10.3350/cmh.2020.0239
|
| 35 |
Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho, Adelino Leite‐Moreira. Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials. Diabetes/Metabolism Research and Reviews 2021; 37(6) doi: 10.1002/dmrr.3413
|
| 36 |
Mani Pathak, Rizwana Parveen, Parvej Khan, Nilanjan Saha, Nidhi Agarwal. Impact of tofogliflozin on hepatic outcomes: a systematic review. European Journal of Clinical Pharmacology 2023; 79(10): 1281 doi: 10.1007/s00228-023-03537-w
|
| 37 |
Manpreet S. Mundi, Saketh Velapati, Janki Patel, Todd A. Kellogg, Barham K. Abu Dayyeh, Ryan T. Hurt. Evolution of NAFLD and Its Management. Nutrition in Clinical Practice 2020; 35(1): 72 doi: 10.1002/ncp.10449
|
| 38 |
Tiantian Song, Shuchun Chen, Hang Zhao, Fei Wang, Huan Song, Dongliang Tian, Qiwen Yang, Licui Qi. Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease. Hepatology Research 2021; 51(6): 641 doi: 10.1111/hepr.13645
|
| 39 |
Hailemichael Desalegn, Renata Farias, David Hudson, Francisco Idalsoaga, Daniel Cabrera, Luis Antonio Diaz, Juan Pablo Arab. Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease. Metabolism and Target Organ Damage 2024; 4(3) doi: 10.20517/mtod.2024.30
|
| 40 |
Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar. Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients. International Journal of Diabetes in Developing Countries 2022; 42(2): 290 doi: 10.1007/s13410-021-00980-2
|
| 41 |
Xiuying Gao, Chuanming Zhu, Wei Zhu, Lin Wang. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes. Biomedical Reports 2024; 22(2) doi: 10.3892/br.2024.1904
|
| 42 |
Ayako Shigeta, Masami Tanaka, Shu Meguro, Jiro Morimoto, Takatoshi Imai, Akira Yamauchi, Yasuhiko Kanazawa, Toshihide Kawai, Koichiro Azuma, Satoru Yamada, Sho Endo, Hiroshi Itoh, Kaori Hayashi. Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study). Journal of Diabetes Investigation 2025; doi: 10.1111/jdi.70018
|
| 43 |
T. Yu. Demidova, D. V. Skuridina, E. S. Pervushina. Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs. FOCUS. Endocrinology 2023; 4(1): 6 doi: 10.15829/2713-0177-2023-17
|
| 44 |
Satish K. Garg, Scott Brackett, Trenton Reinicke, Irl B. Hirsch. New Medications for the Treatment of Diabetes. Diabetes Technology & Therapeutics 2020; 22(S1): S-149 doi: 10.1089/dia.2020.2512
|
| 45 |
Daniela Maria Tanase, Evelina Maria Gosav, Claudia Florida Costea, Manuela Ciocoiu, Cristina Mihaela Lacatusu, Minela Aida Maranduca, Anca Ouatu, Mariana Floria. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Diabetes Research 2020; 2020: 1 doi: 10.1155/2020/3920196
|
| 46 |
Mao-Bing Chen, Rui-Jun Xu, Qi-Han Zheng, Xu-Wen Zheng, Hua Wang. Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus. Medicine 2020; 99(33): e20875 doi: 10.1097/MD.0000000000020875
|
| 47 |
Xinyu Jia, Mengyuan Li, Wen Zhang, Yihui Guo, Fuyu Xue, Shiqi Ma, Shuo Yu, Zhen Zhong, Haipeng Huang. “Adjusting internal organs and dredging channelon” electroacupuncture glycolipid metabolism disorders in NAFLD mice by mediating the AMPK/ACC signaling pathway. Diabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01416-7
|
| 48 |
Yangping Shentu, Yuyang Li, Shicheng Xie, Huanchang Jiang, Shicheng Sun, Rixu Lin, Chaosheng Chen, Yongheng Bai, Yu Zhang, Chenfei Zheng, Ying Zhou. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling. International Immunopharmacology 2021; 93: 107374 doi: 10.1016/j.intimp.2021.107374
|
| 49 |
Iu.G. Samoilova, M.V. Matveeva, A.E. Stankova, D.V. Podchinenova, D.A. Kudlay, O.E. Vaizova, I.R. Grishkevich. Effect of genetic polymorphisms on the effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in treatment of type 2 diabetes mellitus. Profilakticheskaya meditsina 2024; 27(1): 67 doi: 10.17116/profmed20242701167
|
| 50 |
Rebecca K. Vincent, David M. Williams, Marc Evans. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?. Diabetes, Obesity and Metabolism 2020; 22(12): 2227 doi: 10.1111/dom.14196
|
| 51 |
Ralf Glatthar, Robert H. Arch. Burger's Medicinal Chemistry and Drug Discovery. 2021; : 1 doi: 10.1002/0471266949.bmc274
|
| 52 |
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, Marjo Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Ahad Eshraghian, Haluk Tarik Kani, Wafaa Khannoussi, Laurence Lacaze, Miguel Léon-Sanz, Juan M. Mendive, Michael W. Müller, Johann Ockenga, Frank Tacke, Anders Thorell, Darija Vranesic Bender, Arved Weimann, Cristina Cuerda. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline. Clinical Nutrition 2022; 41(10): 2364 doi: 10.1016/j.clnu.2022.07.003
|
| 53 |
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01119-3
|
| 54 |
Qingjuan Zuo, Guorui Zhang, Lili He, Sai Ma, Huijuan Ma, Jianlong Zhai, Zhongli Wang, Tingting Zhang, Yan Wang, Yifang Guo. Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice. Drug Design, Development and Therapy 2022; : 4161 doi: 10.2147/DDDT.S388823
|
| 55 |
Zuo-Di Fu, Xiao-Ling Cai, Wen-Jia Yang, Ming-Ming Zhao, Ran Li, Yu-Feng Li. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World Journal of Diabetes 2021; 12(1): 84-97 doi: 10.4239/wjd.v12.i1.84
|
| 56 |
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine 2021; 10(9): 2040 doi: 10.3390/jcm10092040
|
| 57 |
Dimitrios Patoulias, Michael Doumas. Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. European Journal of Gastroenterology & Hepatology 2020; 32(3): 460 doi: 10.1097/MEG.0000000000001591
|
| 58 |
Emily Truong, Mazen Noureddin. The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. Clinics in Liver Disease 2022; 26(2): 213 doi: 10.1016/j.cld.2022.01.008
|
| 59 |
Mohammed Ali Gameil, Mohammed Shereif Abdelgawad, Monir Hussein Bahgat, Ahmed Hassan Elsebaie, Rehab Elsayed Marzouk. Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. The Egyptian Journal of Internal Medicine 2020; 32(1) doi: 10.1186/s43162-020-00013-0
|
| 60 |
Syeda Hoorulain Ahmed, Abdul Moeed, Eisha Waqar, Sahar Rizwan, Nimra Hasnain, Mohammad Aadil Qamar, Kaneez Fatima, Abdul Mannan Khan Minhas. Efficacy of sodium-glucose co-transporter 2 inhibitors in treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Obesity Medicine 2022; 33: 100437 doi: 10.1016/j.obmed.2022.100437
|
| 61 |
Krishna G. Seshadri, Dakshata Padhye, Surekha Tippisetty, Subhadra Polisetti, Smriti Gadia. Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India. International Journal of Clinical Metabolism and Diabetes 2025; 1(1): 11 doi: 10.1177/30502071241281419
|
| 62 |
Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile. Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis. Advances in Therapy 2021; 38(8): 4195 doi: 10.1007/s12325-021-01791-x
|
| 63 |
Erifili Hatziagelaki, Stavroula A. Paschou, Martin Schön, Theodora Psaltopoulou, Michael Roden. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends in Endocrinology & Metabolism 2022; 33(11): 755 doi: 10.1016/j.tem.2022.08.001
|
| 64 |
Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han. Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia. Reviews in Cardiovascular Medicine 2023; 24(6) doi: 10.31083/j.rcm2406173
|
| 65 |
Agnieszka Polecka, Natalia Olszewska, Łukasz Danielski, Ewa Olszewska. Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review. Journal of Clinical Medicine 2023; 12(19): 6139 doi: 10.3390/jcm12196139
|
| 66 |
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, Giorgia Beatrice, Giovanni Targher. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites 2020; 11(1): 22 doi: 10.3390/metabo11010022
|
| 67 |
Koichi Yabiku. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.768850
|